Europa are delighted to link with I3E and look forward to early September Serenity appraisal spud. Watch the full video here.
Lex in the FT was drawing a direct comparison with the troubles of Bayer with "Roundup" litigation .
To declare in interest I sold out my entire holding last week after holding them since I don't know when.
Analysts at ShoreCap reiterated their 'buy' recommendation for shares of drugs giant AstraZeneca, describing its second quarter top-line growth of 37% year-on-year at constant exchange rates "impressive". "AZN have delivered a strong second quarter, with Q2 benefitting from a full quarter of Alexion integration and several products beating consensus expectations," analyst Dr.Susie Jana said in a research note sent to clients. "Oncology was in line overall due to strong commercial execution and lower COVID-19 related headwinds than anticipated." The analyst also called attention to the fact that AstraZeneca was reinvesting its strong revenues into research and development. And there was more yet to come. "AZN has a strong mid to late-stage pipeline, we expect product and candidate related news flow in 2023 to lead to further upgrades. A strong set of results underpinning the long-term growth story," she added. "AZN shares trade on a FY23F PER of 16.8x, a c 5% premium versus US and European peers (mean 16.1x), which we believe is warranted based on its industry-leading earnings growth and pipeline prospects."
(Sharecast News) - Credit Suisse has initiated coverage of Haleon, GlaxoSmithKline's recently spun out consumer healthcare arm, at 'outperform' with a 368p price target.
The bank said Haleon is a "highly attractive" company. It said that as the only listed pure-play in Consumer Health - an industry with structural growth trends - Haleon's current valuation fails to recognise the company's scope to deliver above-guidance organic sales growth of 6.5% in FY22, followed by 4.5% in FY23.
It also fails to recognise the improved portfolio of the business (post recent M&A and divestments) and its ability to leverage scale as the clear global leader, with a market share twice that of its nearest competitor.
Credit Suisse said that based on its analysis of more than 100 country/category cell forecasts, it expects Haleon to deliver 4.2% organic sales growth per annum over the medium term, which reflects around 10 basis points a year market-share expansion.
CS said Haleon has high-quality earnings growth potential of circa 7.5% per year, benefitting from further margin expansion and reduced interest cost.
"Compared to consumer staples, the company has a relatively low exposure to input costs (less than 10% of sales) and emerging market currencies, and is likely more resilient in an economic downturn, in our view," it said.
It added that the step-up in cash conversion should allow the group to de-lever quickly.
I originally got my Standard Life shares as a policy holder when they demutualised. These then became Abrdn shares following the merger.
Can anyone remember what the value was at that time?
I have recently sold my Abrdn and I am trying to work out whether I have a CGT liability in the sale.
UBS research on Tuesday downgraded AstraZeneca (NASDAQ:AZN) stock to neutral from buy, citing no major catalysts on their radar for the Anglo-Swedish drug giant until Q1 next year.
U.S.-listed shares of AZN were down 1.3% at $59.22 in mid-day trading amidst mixed broader markets.
"On the back of impressive trial results for (cancer drugs) Lynparza and Enhertu, AZN has outperformed the global large cap peer group by 120bps this year," said UBS analysts Michael Leuchten, Laura Sutcliffe and Colin White.
However, the stock is now in more "sensible territory," the analysts said, adding that the rest of the year would be more about commercial execution.
"In times of reduced pipeline noise, the market tends to focus more on AZN's margin progression and we suspect this time it will be no different with some additional debate around the trajectory in China," they said.
UBS said now that major trial readouts for the year were done, the focus would return to the performance of Lynparza, along with other cancer drugs Tagrisso and Calquence.
Calquence, Lynparza and Tagrisso brought in total revenue of $414M, $792M and $1.30B, respectively, for AZN in Q1.
The UBS analysts also said that they see little potential for Alexion to deliver any meaningful upside. AZN completed its acquisition of U.S.-based Alexion in July last year.
Up to Monday's close, AZN stock +3% YTD.
Analysts at JP Morgan hiker their target price for shares of AstraZeneca and pointed to the potential for "significant" future upward revisions to analysts' estimates for the profitability of the company's oncology pipeline. The latter, they said, should help drive a further re-rating in the share price. In particular, they focused on the potential for Enhertu and DS-1062 Antibody Drug Conjugate for HER2-expressing cancer and TROP2-expressing cancer, respectively. Combined, they forecast the two treatments were capable of generating combined in-market peak annual sales of over $20bn - shares with partner Daiiichi - with the potential for significant long-term upgrades over the following 12 months. For Enhertu, a DB-04 PIII data presentation was scheduled for June 2022, headline DB-06 PIII data in mid-2023 and additional readouts in 2024-25. In the case of DS-1062, the first PIII data was expected in late 2022 or early 2023 with read-through to further PIII data in approximately 2025. On the back of all of the above, JP Morgan raised its target price for the shares from 10,000.0p to 12,000.0p and reiterated its 'overweight' rating. The analysts' estimates for Enhertu and DS-1062 were 20% and 75% ahead of the company consensus for 2027.
Drugmaker AstraZeneca revealed on Tuesday that its Ondexxya asset had become the first approved medicine in Japan to specifically reverse the anticoagulant effect of Factor Xa inhibitors, providing "a major advance" in the treatment of patients hospitalised with life-threatening bleeding. AstraZeneca stated the approval by the Japanese Ministry of Health, Labour and Welfare was based on positive results from its ANNEXA-4 Phase III clinical trial, which showed Ondexxya "rapidly and markedly" reversed anti-FXa activity in patients with acute major bleeding. Ondexxya received US approval from the Food and Drug Administration under the accelerated approval pathway in May 2018 and conditional approval by the European Commission in April 2019 for adults treated with FXa inhibitors apixaban and rivaroxaban. Mene Pangalos, AstraZeneca's executive vice president of biopharmaceuticals R&D, said: "With the approval of Ondexxya in Japan, we are working to make this important medicine available as quickly as possible for the small proportion of patients with life-threatening or uncontrolled bleeding who are on FXa inhibitors and who have not previously had an approved reversal agent treatment option."
AstraZeneca's rare disease unit has entered into a settlement agreement with Chugai Pharmaceutical, resolving all patent disputes between the two companies related to long-acting C5 complement inhibitor, Ultomiris (ravulizumab). In accordance with the settlement agreement, AZN's Alexion wing and Chugai have both taken steps to withdraw patent infringement proceedings filed in the US with the District Court of Delaware and in Japan with the Tokyo District Court. Under the terms of the agreement, Alexion will make a single payment of $775.0m in the second quarter of 2022, for which a charge will be recognised through non-core profit and loss in the first quarter of 2022. AZN added that no further amounts will be payable by either party and said the settlement did not impact the group's financial guidance for 2022. Alexion chief executive Marc Dunoyer said on Thursday: "With this settlement, we will continue to advance our Ultomiris development programmes in new indications and focus on our mission to transform the lives of people affected by rare diseases."
AstraZeneca said on Monday that Lynparza candidate had been approved in the US as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. AstraZeneca said on Monday that the approval by the Food and Drug Administration was based on results from its OlympiA Phase III trial, which demonstrated a "statistically significant and clinically meaningful improvement" in invasive disease-free survival, reducing the risk of invasive breast cancer recurrences, second cancers or death, by 42% versus a placebo. AZN's Dave Fredrickson said: "This important approval gives early-stage breast cancer patients in the US with a germline BRCA mutation a new targeted therapy option in the adjuvant setting starting today. "Lynparza reduces the risk of disease recurrence in these high-risk patients and now new data confirm it also significantly extends patients' lives versus placebo. These data underline the importance of germline BRCA testing as soon as possible after diagnosis to identify patients that may be eligible for Lynparza." Separately, AstraZeneca said the Food and Drug Administration had issued a complete response letter regarding the supplemental Biologics License Application for its Fasenra candidate for patients with inadequately controlled chronic rhinosinusitis with nasal polyps. The letter requested AZN supply additional clinical data, with the company now working closely with the FDA regarding next steps as it "remains committed to bringing Fasenra to patients". A second Phase III trial on the drug was ongoing
Drugmaker AstraZeneca said on Tuesday that its rare diseases subsidiary had closed an exclusive global collaboration and licence agreement with Neurimmune for NI006, an investigational human monoclonal antibody currently in Phase Ib development.
AstraZeneca said its Alexion subsidiary had been granted an exclusive worldwide licence to develop, manufacture and commercialise NI006, which will be used for the treatment of transthyretin amyloid cardiomyopathy, an under diagnosed, systemic condition that leads to progressive heart failure and a high rate of fatality within four years from diagnosis.
Under the terms of the agreement, Alexion will make an upfront payment of $30.0m to Neurimmune, while there will also be additional contingent milestone payments of up to $730.0m upon achievement of certain development, regulatory and commercial milestones. It will also pay "low-to-mid teen royalties" on net sales of any approved medicine resulting from the collaboration.
AZN added that Neurimmune will continue to be responsible for the completion of the current Phase Ib clinical trial, while Alexion will pay certain trial costs and be responsible for further clinical development, manufacturing and commercialisation following the trial.
straZeneca (NASDAQ:AZN) said on Feb. 17 that the European Medicines Agency accepted its application for nirsevimab under an accelerated assessment for the prevention of lower respiratory tract infections (LRTI) in all infants through their first respiratory syncytial virus (RSV) season.
The British drugmaker is developing nirsevimab in collaboration with Sanofi (NASDAQ:SNY).
AstraZeneca said nirsevimab is the first investigational long-acting antibody designed to provide RSV protection for all infants.
It is being developed as a single dose for infants experiencing their first RSV season and for children at higher risk in their second RSV season.
The company's Marketing Authorization Application (MAA) is backed by data from the MELODY Phase 3 trial, MEDLEY phase 2/3 study, and phase 2b trial which showed nirsevimab’s safety and efficacy in providing protection against the virus for all infants with a single dose for the RSV season.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) granted nirsevimab accelerated assessment, which aims to reduce the timeframe for the CHMP to review a MAA compared to the standard procedure and follows the EMA granting access to the PRIority MEdicines (PRIME) scheme in 2019.
The company said additional regulatory submissions are planned to take place in 2022.
"I would strongly advise you shorters to start selling your borrowed shares as soon as you can." So you are encouraging Shorting are you?
For those that don't know The object of borrowing shares is to sell what you don't own in the hope/belief that the share price will fall. Eventually the short has to be covered by buying shares back so that they can be given back to their original owner.
If they buy back at a lower price than they sold at then they are in profit. The danger is that the share price unexpectedly rises and then loses can be immense as come what may they same number of shares has to be bought.
Now there is the argument that vultures perform a valuable service by removing dead carrion from the savannah.
1. Go to https://www.gov.uk/government/organisations/companies-house
2. select Find company information
3. scroll down & click Start Now.
4 Search the register will open. Enter Avacta
5. Click on Avacta Group PLC
6. On the next page select Filing History
7 Lots of choice but I'd selected Companies Account & filed on 07/07/2021
8 Down load pdf -135 pages worth!
8. Lots of other goodies to brows on the site.
I hope that this works.
You can find all sorts of things by looking on the web site for Companies House. Lots of info on Avacts.
Some of you my find this document interesting.
AstraZeneca said its Enhurtu breast cancer drug had demonstrated a "statistically significant and clinically meaningful improvement" in survival a phase three trial versus chemotherapy.
AstraZeneca stated DESTINY-Breast04 met its primary endpoint, where Enhertu demonstrated "superior" PFS in previously treated patients with HR-positive HER2-low metastatic breast cancer compared to the standard-of-care chemotherapy.
The company, which is working on the drug with Japan's Daiichi Sankyo, said Enhertu prolonged survival and slowed the progression of metastatic breast cancer in women with low levels of a protein known as HER2.
Enhertu also met its key secondary endpoint of progression-free survival in patients with HER2-low metastatic breast cancer regardless of hormone receptor status and also met its key secondary endpoints of overall survival in patients with HR-positive disease and in patients regardless of hormone receptor status at interim analysis.
Susan Galbraith, AstraZeneca's executive vice-president of oncology R&D said: "Today's historic news from DESTINY-Breast04 could reshape how breast cancer is classified and treated. A HER2-directed therapy has never-before shown a benefit in patients with HER2-low metastatic breast cancer." "These results for Enhertu are a huge step forward and could potentially expand our ability to target the full spectrum of HER2 expression, validating the need to change the way we categorise and treat breast cancer."
Pharmaceutical company AstraZeneca said on Tuesday that results from a recent study revealed that its Lynparza asset reduced the risk of first-line metastatic castration-resistant prostate cancer progression by 34% when used in combination with abiraterone. AstraZeneca stated the combination demonstrated "a statistically significant and clinically meaningful improvement" in radiographic progression-free survival versus current standard-of-care. Susan Galbraith, AZN's executive vice president of Oncology R&D, said: "This Lynparza combination has the potential to afford first-line patients more time without disease progression while also maintaining their quality of life. "The PROpel results are impressive because active comparator trials set a high bar and, in this trial, Lynparza plus abiraterone showed a significant clinical improvement when compared to an active standard of care in patients with metastatic castration-resistant prostate cancer, regardless of whether they have an HRR gene mutation."
AstraZeneca announced the first increase to its dividend for a decade and an upbeat outlook as the drugs company swung to a fourth-quarter loss driven by higher costs. The drugs company posted a $636m pretax loss for the three months to the end of December from a $1.49bn profit a year earlier as revenue rose 62% to $12bn. The cost of sales rose to $4.63bn from $1.53bn. Core earnings rose 56% to $1.67 in the fourth quarter. That figure excludes items related to acquisitions, amortisation of intangibles and restructuring costs. The company declared a second interim dividend of $1.97 a share, taking the annual payout to $2.87. AstraZeneca said it intended to increase the annualised dividend by $0.10 to $2.90, "reflecting increased confidence in future growth and cash generation". The increase is the first for 10 years. Shares of AstraZeneca rose 3.8% to £86.81 at 08:56 GMT and were the biggest gainers in the FTSE 100 index. AstraZeneca's Vaxzevria coronavirus vaccine added $1.76bn to fourth-quarter revenue and $3.98bn to income for the full year. AstraZeneca swung to an annual pretax loss of $265m from a $3.92bn profit a year earlier as costs more than doubled to $12.44bn from $5.3bn. AstraZeneca said it expected revenue to rise by a mid-teens percentage in 2022 and for core earnings per share to increased by a percentage in the mid-to-high 20s. The FTSE 100 group predicted Covid-19 revenue would decline by a percentage in the low-to-mid 20s and that the gross profit margin from Covid-19 sales would be lower than the company average. The company bought Alexion, a US biotech specialising in rare diseases, in July for $39bn to deepen its focus on immunology and strengthen its position in the US. Pascal Soriot, AstraZeneca's chief executive, said: "AstraZeneca continued on its strong growth trajectory in 2021. The positive news from our pipeline, including approvals for Evusheld and Tezspire, supports the outlook for 2022. This, along with the transformative acquisition of Alexion, means that we are confident in our long term growth and profitability. After a landmark year in 2021, we are increasing the dividend for our shareholders." AstraZeneca makes one of the leading Covid-19 vaccines, developed with Oxford University, and has also produced a coronavirus prevention treatment, Evusheld. Tezspire, an asthma treatment, was also approved in 2021. The company has 13 so-called blockbuster medicines. Five of these crossed annual revenue thresholds including Tagrisso, which sold more than $5bn, and Farxiga, which passed the $3bn mark. Keith Bowman, an analyst at Interactive Investor, said: "Core earnings per share of $1.67 [were] at the upper end of forecasts. Some 22 regulatory drug approvals during 2021 continue to underline its innovation, with a marginal increase in the annual dividend also suggesting long term confidence."